We are following closely the progress of Dupixent®  (Dupilumab) a drug that has been approved in the US at treatment for both for Eosinophilic Asthma and Atopic Dermatitis.

Now in phase 3 trials for Eosinophilic Oesophagitis for patients 12 years and older in 88 centres around the globe and currently showing promising results at remaining effective for EoE for up to 2 years.

Check out Dr Evan Dellon giving a video update at the American College of Gastroenterology  HCP Live Video Update

Link for full clinal trial details 

Would you like to be kept up to date on all news including research and clinical trials ? 

Register with us